Reata Pharmaceuticals to Submit Omaveloxolone for NDA in Early 2022
In a press release following the completion of pre-NDA meeting with the FDA, Reata Pharmaceuticals (RETA) stated that the purpose of the pre-NDA meeting was to discuss the content of Reata’s planned NDA submission. The firm plans to submit the NDA . . .
This content is for paid subscribers.
Today’s Highlights September 30, 2021